The registration of the cancer follow-on biological product was published in the country’s Official Gazette (Diário Oficial da União) on 16 May 2019. The company submitted the application for approval in Brazil 13 months earlier, in December 2017.

Ontruzant has been approved in Brazil to treat patients with early breast cancer, metastatic breast cancer and metastatic gastric cancer.

The Brazilian approval marks the fourth approval for the trastuzumab product from Samsung Bioepis. The company gained Korean approval for Samfenet (trastuzumab) in November 2017 [1], European approval for Ontruzant in November 2017 [2] and US approval for Ontruzant in January 2019 [3].

Related articles
Brazil approves first monoclonal antibody follow-on biological

Similar biotherapeutic products approved and marketed in Latin America

References
1. GaBI Online - Generics and Biosimilars Initiative. Adalimumab and trastuzumab biosimilars approved in South Korea [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/Adalimumab-and-trastuzumab-biosimilars-approved-in-South-Korea
2. GaBI Online - Generics and Biosimilars Initiative. EC approval for trastuzumab biosimilar Ontruzant [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-trastuzumab-biosimilar-Ontruzant
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves trastuzumab biosimilar Ontruzant [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-trastuzumab-biosimilar-Ontruzant

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.